To identify the sub-population of TNBC patients who may potentially benefit from treatment with selinexor, we assessed the levels of ARRDC3, XPO1 and ITG β4 from normal biopsy tissue as well as in 114 biopsies of TNBC patient tumor samples (Figure 4). This evidence concerns the gene ARRDC3 and neoplasm.